Uncategorized

The Generic Drug Approval Process: A Complete Technical and Strategic Reference for Pharma IP, R&D, and Investment Teams

Generic drugs don’t “just happen.” Behind every approved ANDA sits a high-stakes, technically precise process that can make or break pharma IP strategy, R&D planning, and investment theses. If you’re an IP leader, R&D executive, or investor und…

The Generic Drug Approval Process: A Complete Technical and Strategic Reference for Pharma IP, R&D, and Investment Teams Read Post »

Uncategorized

CDMO Project Management: The Definitive Playbook for Pharma IP Teams, R&D Leads, and Institutional Investors

Pharma IP teams don’t lose deals because they lack patents. They lose them because the work behind the patents is mismanaged.
That’s the uncomfortable truth hiding in plain sight: in modern drug development, “project management” isn’t an operational af…

CDMO Project Management: The Definitive Playbook for Pharma IP Teams, R&D Leads, and Institutional Investors Read Post »

Uncategorized

Your Drug’s Patent Expired. Now What? The Complete Strategic Guide to Patent Cliffs, Lifecycle Defense, and Post-Exclusivity Competition

Your drug’s patent just expired. That moment feels like a cliff—until you realize it’s a lifecycle.
In pharma, “patent expiration” is rarely a single event. It’s the visible edge of a much longer timeline: exclusivity windows, regulatory milestones, ma…

Your Drug’s Patent Expired. Now What? The Complete Strategic Guide to Patent Cliffs, Lifecycle Defense, and Post-Exclusivity Competition Read Post »

Biotechblog
Scroll to Top